Eli Lilly, the manufacturer of tirzepatide, never submitted clinical trial data for an oral formulation because developing one that achieves adequate bioavailability remains a significant pharmaceutical challenge
However, extensive evidence links both obesity and diabetes with ED, (07:00): with positive indications that improvements in these conditions result in better sexual function
These medications can slow tumor growth and control symptoms associated with hormone-producing tumors

Lillys eloralintide (amylin receptor agonist), providing a potential option for Lilly to defend against amylin analogues, including Novo Nordisks CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide and semaglutide, or Zealands petrelintide (phase 2) Structure Therapeutics GSBR-1290 (GLP-1), small molecule, oral obesity therapy, seeking to substantiate its earlier, positive phase 2a data to deliver competitive weight loss, against both other oral therapies and marketed injectables, with acceptable tolerability (phase 2b) Crucially, a number of phase 3 readouts in 2025 for key AOM assets will set the stage for their launch in 2026, when the next wave of AOMs enter the market to re-shape the competitive landscape: Lillys orforglipron (GLP-1), one of the first oral AOMs to launch, possibly alongside oral semaglutide, and when it does, the first small molecule based therapy in the market

Over-the-counter gas relief products may also provide temporary relief, and consistent use of a probiotic can improve the GLP1 gut health effects